Biodexa Pharmaceuticals sees cash runway into 1Q26
As of May 29, 2025, the Company had access to the following cash resources: Cash at bank $5.7M; Cash in escrow for eRapa Phase 3 program $4.4M; Undrawn CPRIT grant for eRapa Phase 3 program $11.9M; Debt $0.5M. The CPRIT grant, together with Company match means the eRapa Phase 3 program is substantially funded. Based on its latest projections, the Company has sufficient working capital to fund operations into the first quarter of 2026. Issued shares, total voting rights, market capitalization As of May 29, 2025, there were 50,506,308,922 ordinary shares, equivalent to 5,050,630 American Depositary Shares, outstanding. The Company holds zero shares in treasury and therefore the number of voting rights is the same as the number of ordinary shares outstanding. Based on the closing share price on May 29, 2025 of $1.06 per ADS, the Company's market capitalization was $5.4M.The Phase 3 study of eRapa in FAP is in the final stages of implementation. It will be a double-blind placebo-controlled trial in 168 patients, randomized 2:1 drug / placebo. It is expected the study will be conducted in approximately 30 clinical sites across the US and Europe. The US component of the study will be conducted by LumaBridge, based in San Antonio, Texas and the European component will be conducted by Precision for Medicine. All planned US sites and the majority of European sites have been identified. Recruitment is expected to begin in the next few weeks.
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders' Hot Stocks on TipRanks >>
Read More on BDRX:
Disclaimer & DisclosureReport an Issue
Biodexa Pharmaceuticals Releases 2024 Annual Report and Announces AGM
Biodexa Pharmaceuticals Plans Share Capital Reorganization and New Share Allotment
Biodexa Pharmaceuticals Secures Additional $3M Grant for eRapa Phase 3 Program
Biodexa Pharmaceuticals announces award of additional $3M grant from CPRIT
Biodexa Pharmaceuticals Lowers Warrant Exercise Price to Boost Capital
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
23 minutes ago
- Bloomberg
Morgan Stanley Sees Dollar Falling 9% on Slowing US Growth Bets
The dollar will tumble to levels last seen during the Covid-19 pandemic by the middle of next year, hit by interest rate cuts and slowing growth, according to predictions by Morgan Stanley. A popular gauge of the dollar will fall around 9% from current levels by around this time next year, strategists including Matthew Hornbach predicted in a May 31 note. That will exacerbate a recent decline in the greenback, as trade turmoil weighs on the currency.
Yahoo
28 minutes ago
- Yahoo
'It Won't Be China That Takes Control — It'll Be Musk': Enrique Abeyta Says Trump's AI Order Hands Elon the Reins of America's Machine Future
WASHINGTON, June 01, 2025 (GLOBE NEWSWIRE) -- Most headlines worry about foreign AI dominance. But former hedge fund manager Enrique Abeyta sees a different threat rising from within. Abeyta explains in his recent briefing that with Elon Musk's AI supercomputer Dojo accelerating toward national rollout — and President Trump's executive order removing the last legal barriers — Abeyta warns: 'It won't be China that runs the machine economy. It'll be Musk.' 'Trump just ensured Dojo stays American. But in the process, he handed Musk the keys.' Domestic Superpower: What Musk Built Dojo isn't just a chip or a data project. It's a complete, real-time AI system that's: Trained on 160 billion frames of daily real-world video Built on a proprietary chip 6x faster than Nvidia's top processor Designed to control machines in motion — not simulations Tesla's next step? The June 1st launch of a fully autonomous robotaxi — no pedals, no steering wheel, no driver. Trump's Order Removes the Last Obstacle President Trump's 'Removing Barriers to American AI Innovation' executive order gives domestic AI leaders unprecedented freedom to develop and deploy systems like Dojo without traditional oversight. One key partner in Musk's AI ecosystem is already 'expecting to receive billions of dollars from the Trump administration.' The stated goal: outpace China. The result? Musk now operates the fastest, most government-aligned AI infrastructure in the country. About Enrique Abeyta Enrique Abeyta is a former hedge fund manager who tracked high-level capital movements and strategic shifts across markets, infrastructure, and policy. After managing nearly $4 billion in institutional capital, he now leads Breaking Profits, a research platform dedicated to exposing the next generation of power systems shaping America's future. Media Contact:Derek WarrenPublic Relations ManagerParadigm Press GroupEmail: dwarren@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wall Street Journal
31 minutes ago
- Wall Street Journal
Asian Currencies Consolidate; U.S. Steel, Aluminum Tariffs May Buoy
0036 GMT — Asian currencies consolidate against the dollar in the morning session, but may be buoyed by President Trump's announcement to double U.S. tariffs on imports of steel and aluminum to 50% from June 4. 'The USD is at the lower end of fair value, according to our metrics,' three members of CBA's Global Economic & Markets Research say in a research report. 'The risk is U.S. trade policy changes pull the USD below the fair value range,' the members add. The ICE USD Index is down 0.1% at 99.20; USD/JPY edges 0.1% lower to 143.67; USD/PHP is little changed at 55.80. (
